Brii Biosciences Limited, a biotechnology company, announced that it has entered into agreements with VBI Vaccines Inc., to expand the clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio's HBV functional cure portfolio. Financial terms were not disclosed. Durham, North Carolina-based Brii was advised by a Cooley team led by Rama Padmanabhan, Rajdeep Bains, Jason Savich, Lila Hope, Michael Klein, Michelle Schulman, Yiming Liu, Matthew Scarano, Jameson Davis and Kaiting Yan.
Biotech & Pharmaceuticals
February 15, 2024, 12:54 PM